CAbotégravir LENacapavir DUal Long Acting

Age ≥ 18 years * HIV-1 infection * Stable oral antiretroviral treatment for at least 6 months * Multi-treated patients who have received multiple lines of antiretroviral treatment * Undetectable patients with CV \< 50 copies/mL in the last 6 months (a single blip between 50 and 200 copies/mL in the last 6 months is allowed) and eligible to switch to the lenacapavir/cabotegravir strategy on the basis of a collegial decision by clinicians, virologists and pharmacologists following a multidisciplinary meeting due to * the presence of resistance mutations, including to NNRTIs * or oral drug intolerance * or drug-drug interactions * Detectable, virologically uncontrolled HIV viral load ≥ 200 c/mL in the last 12 months who is eligible to switch to the lenacapavir/cabotegravir strategy based on a collegial decision by clinicians, virologists and pharmacologists following a multidisciplinary meeting due to * the presence of resistance mutations, including to NNRTIs * or oral drug intolerance * or drug-drug interactions * ASAT and ALAT \< 3N * Creatinine GFR \> 60 mL/min (CKD-EPI) * Haemoglobin \> 10 g/dL * Platelets \> 100 000/mm3 * Commitment to use preventive and protective means of sexual intercourse for the duration of the trial. * For women at risk of pregnancy, commitment to use an effective method of contraception for the duration of the study. * Affiliated or beneficiary of a social security scheme (article L1121-11 of the French Public Health Code), * Free, informed, written consent, signed by the person and the investigator no later than the day of inclusion and before any examination carried out as part of the study (article L1122-1-1 of the French Public Health Code). Non-inclusion criteria * HIV-2 infection or HIV-1/HIV2 co-infection * HIV-1 subtype A6/A1 * BMI ≥ 30kg/m². * Chronic active viral hepatitis B with positive Hbs antigen * Active chronic viral hepatitis C requiring specific treatment over the next 48 weeks. * Treatment with interferon, interleukin or any other immunotherapy or chemotherapy in progress. * Active opportunistic infection, or acute treatment for opportunistic infection * Any condition (alcohol, drugs, neurological or neuropsychiatric disorders, etc.) likely to compromise tolerance of treatment and/or patient compliance with treatment and adherence to the protocol, as judged by the investigator. * Women who are breastfeeding, pregnant or refusing contraception * Taking medication contraindicated with the trial treatment * Major incapacity, legal protection, guardianship or curatorship * Planning to move house within the next 18 months